
==== Front
J Oncol
J Oncol
jo
Journal of Oncology
1687-8450
1687-8469
Hindawi

10.1155/2021/5936905
Research Article
Transcriptional and Epigenetic Bioinformatic Analysis of Claudin-9 Regulation in Gastric Cancer
https://orcid.org/0000-0003-4347-4276
Hernández-Nava Elizabeth
https://orcid.org/0000-0002-2019-3140
Montaño Luis F.
https://orcid.org/0000-0001-6648-582X
Rendón-Huerta Erika P. erendon@unam.mx

Laboratorio Inmunobiología, Departamento Biología Celular y Tisular, Facultad de Medicina, UNAM, Mexico City, Mexico
Academic Editor: Yuan Seng Wu

2021
18 12 2021
2021 593690513 9 2021
15 11 2021
30 11 2021
Copyright © 2021 Elizabeth Hernández-Nava et al.
2021
https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Gastric cancer is a heterogeneous disease that represents 5% to 10% of all new cancer cases worldwide. Advances in histological diagnosis and the discovery of new genes have admitted new genomic classifications. Nevertheless, the bioinformatic analysis of gastric cancer databases has favored the detection of specific differentially expressed genes with biological significance. Claudins, a family of proteins involved in tight junction physiology, have emerged as the key regulators of cellular processes, such as growth, proliferation, and migration, associated with cancer progression. The expression of Claudin-9 in the gastric cancer tissue has been linked to poor prognosis, however, its transcriptional and epigenetic regulations demand a more comprehensive analysis. Using the neural network promoter prediction, TransFact, Uniprot-KB, Expasy-SOPMA, protein data bank, proteomics DB, Interpro, BioGRID, String, and the FASTA protein sequence databases and software, we found the following: (1) the promoter sequence has an unconventional structure, including different transcriptional regulation elements distributed throughout it, (2) GATA 4, GATA 6, and KLF5 are the key regulators of Claudin-9 expression, (3) Oct1, NF-κB, AP-1, c-Ets-1, and HNF-3β have the higher binding affinity to the CLDN9 promoter, (4) Claudin-9 interacts with cell differentiation and development proteins, (5) CLDN9 is highly methylated, and (6) Claudin-9 expression is associated with poor survival. In conclusion, Claudin-9 is a protein that should be considered a diagnostic marker as its gene promoter region binds to the transcription factors associated with the deregulation of cell control, enhanced cell proliferation, and metastasis.

Universidad Nacional Autónoma de MéxicoIN218019 IN221519
==== Body
pmc1. Introduction

Gastric cancer is the third leading cause of cancer-related deaths worldwide [1]. There are two main subtypes of gastric cancer, namely intestinal and diffuse. The intestinal type is associated with H. pylori infection, whereas the diffuse type is mainly hereditary and possesses multiple mutations [2, 3]. In the study of gastric cancer, epigenetics has been thought of as a critical factor in developing new strategies for the understanding of molecular processes [4]. The changes in the profile gene expression are the fundamental properties of aggressiveness and good tools in the prognosis of several oncological diseases [5]. New genes in the genomic context are attracting attention by playing essential roles in the progression of the disease [6].

The tight junctions (TJs) are intercellular adhesion complexes located in the apical zone of the lateral membrane of the epithelial and endothelial cells. TJs are essential for barrier function and cell polarity by limiting the movement of the proteins within the plasma membrane and regulating the paracellular solute [7]. TJs are made up of adapter proteins and integral membrane proteins, such as claudins, which are indispensable for TJ strand formation [8]. Claudins, a family of 27 isoforms, which, in addition to having barrier and polarity functions, also function as coreceptors for viruses and bacterial toxins, are coexpressed in specific cell types and are functionally divided into four groups with different functions [9]. The transcription of claudins is tightly controlled by regulatory mechanisms, epigenetic alterations, transcriptional changes, and post-translational modifications [10]. Nevertheless, the understanding of the structure and function of TJ has been amplified as the appearance of chimeric claudins [11]. The repercussion of other components, such as junctional adhesion molecules, zonula occludens proteins, membrane lipids, and mechanical forces, have transformed our knowledge of the structure, dynamic interaction, and function of TJ assembly [12]. Interestingly, the functional crosstalk between TJ proteins and signaling pathways involved in cell proliferation, transformation, and metastasis is becoming a current topic [13].

Claudins play a crucial role in regulating cellular processes such as growth, proliferation, and migration [14, 15]. The disruption of cell-cell junctions results in the loss of cell polarity and has a decisive role in cancer progression [16]. Claudin expression is altered, elevated, and negatively regulated in cancer, but most intriguingly, claudin expression is tumor-specific [17]. Bioinformatics analysis has extensively confirmed the prevalence of claudins in gastric cancer patients [18–22], especially Claudin-6 and -9, which are considered critical factors related to poor prognosis in gastric cancer [23, 24]. Claudin-9 is expressed primarily in the inner ear and is essential for hearing [25], however, its aberrant expression has been reportedly established in lung cancer [26], pituitary oncocytoma [27], and cervical carcinoma [28]. Claudin-9 has been included in a seven-gene signature as a clinical prognosis marker in esophageal adenocarcinoma [29]. Despite the above, there is a limited body of literature that recognizes the significance of Claudin-9 in gastric cancer.

The increase in Claudin-9 expression in the gastric cancer tumor tissue is associated with an increase in cell proliferation and invasion. Furthermore, Claudin-9 overexpression is associated with a higher mortality rate (66%) in diffuse-type gastric cancer [30, 31]. The present work aimed to perform a bioinformatics analysis to understand the mechanisms involved in the transcriptional and epigenetic regulation of Claudin-9 and its repercussions in gastric cancer.

2. Material and Methods

2.1. Claudin 9 (CLDN9) Datasets

CLDN9 gene sequence was obtained from National Center for Biotechnology Information (NCBI, https://www.ncbi.nlm.nih.gov/) (Gene ID: 9080), and a blast was performed to obtain the reference number and the sequence in FASTA format. Subsequently, the Genome Browser database (https://genome.ucsc.edu/) was used to analyze the genomic context of the CLDN9 gene. In the sequence section, upstream of the 5′ end was adjusted to 2500 bp for further promoter analysis.

2.2. Data Processing

Firstly, we look to determine the minimum promoter region using “neural network promoter prediction.” In addition, we evaluated the presence of consensus regulatory sequences, such as CpG islands, TATA, CAAT and GC boxes, GATA, Inr (Initiator), and DPE (downstream promoter element) sequences.

2.3. Prediction of Transcription Factors

TRANScription FACtor database (TRANSFACT; http://gene-regulation.com) was used to identify possible transcription factors and their binding sites in the CLDN9 gene promoter. TRANSFACT uses two algorithms. The first describes the binding sites in the promoters or enhancers, and the second shows the transcription factors. Again, using a 2500 bp sequence upstream of the transcriptional start site of CLDN9, we perform the analysis. The search settings were established in the match: vertebrates, minimize the sum of both errors pattern: 0.7–0.75 cut-off—best selection-prf. A similarity of 100% was considered for further analysis of molecular docking with their corresponding promoter sequence.

We use the Signaling Pathway Project experimental database (https://www.signalingpathways.org/index.jsf), to study the possible transcription factors. The “Ominer” tool (https://www.signalingpathways.org/ominer/query.jsf) was used to discover the relationship between the single gene CLDN9 and the node of transcription factors using cistromics datasets (Chip-Seq) in the bio sample category of human in the stomach tissue.

2.4. Molecular Docking Analyses

Crystal availability and biological relevance in the cancer context were considered for factor selection and molecular docking analysis. The crystallographic structures were obtained from the Protein Data Bank (http://www.rcsb.org/pdb). The Homo sapiens crystals used were OCT-1 (1E3O; 280–438 aa), NF-kappaB (1SVC; 2–365 aa), AP-1 (1JNM; 254–315 aa), C-ets-1 (1GVJ; 297–441 aa), and HNF-3β (5X07; 157–258 aa). Three-dimensional DNA models were built using “The Supercomputing Facility for Bioinformatics & Computational Biology,” IIT Delhi (SCFBio, http://www.scfbio-iitd.res.in/). Docking studies were calculated using different configurations of the HDOCK server (http://hdock.phys.hust.edu.cn/). Finally, the visualization of the molecular models was done using Chimera software ver. 1.11.2.

2.5. Methylation Bioinformatic Analyses

Disease meth version 2.0 database (http://bio-bigdata.hrbmu.edu.cn/diseasemeth/) concentrates the aberrant methylomes of different types of cancer. Methylation was analyzed from the Cancer Genome Atlas (TCGA) Gastric Cancer Patient Data Repository (STAD). The data were obtained using the Illumina Infinitum HumanMethylation 450 Beadchip technology experimental platform (n = 397). The differential analysis method was Student's t-test. P=0.05 was considered a significant value. The absolute methylation difference was set at >0.2. The methylation analysis of the promoter region (2 kB upstream to TSS to 0.5 kB downstream) of CLDN9 was performed using the MethBrowser tool.

Xena server (https://xena.ucsc.edu/) was used to explore the possible associations of the CLDN9 promoter methylation with its expression levels and differential methylation between the histological types. Likewise, the impact of CLDN9 methylation on different clinical consequences, such as overall survival (OS), progression-free interval (PFI), and the disease-free interval was analyzed.

2.6. Structural Characteristic Analyses

For the study of the structure, sequence, and domains of CLDN9, the polypeptide sequence was obtained using the databases Uniprot-KB (https://www.uniprot.org/), secondary structure prediction was determined using Expasy-SOPMA software (https://npsa-prabi.ibcp.fr/cgi-bin/npsa_automat.pl?page=/NPSA/npsa_sopma.html), protein data bank (https://www.rcsb.org/), proteomics DB (https://www.proteomicsdb.org/), and Interpro (https://www.ebi.ac.uk/interpro/). The FASTA protein sequence was used for all analyses. We chose the 095484 entries in UniprotKB, CLDN9_HUMAN entry name, Homo sapiens organism.

In the case of Expasy-SOPMA, we used UNK_645620 ID protein for Claudin-9 [32].

Pharos was used to analyze the data compiled in a knowledge management base taking into account the complexity of the analyzed targets. With this tool, it was sought to efficiently visualize and summarize the results to identify the patterns. The information reviewed and related to Claudin-9 was tissue and cell type, cell component, disease disturbance, genetic alterations, metabolism, molecular function, protein domains, PubMedID, SNP, and transcription factors, among others.

2.7. Protein-Protein Interactions Networks

The general interaction map of Claudin-9 was generated using the String database (https://string-db.org/cgi/input?sessionId=biUPDH3R9Of4&input) to analyze known interactions (from curated databases and experimentally determined), predicted interactions (gene neighborhood, gene fusions, and gene co-occurrence), and others (textmining, coexpression, and protein homology). In String, the lines denote the physical or theoretical interactions, and the ends of each line denote the effect on the protein. In this case, the circle at the end of the line indicates that the result is unknown. The analysis of interaction was performed using confidence fields. The thicker the line and the closer they are to each other, the greater the interaction confidence. Additionally, we used BioGRID (https://thebiogrid.org/) to investigate the physical interaction with Claudin-9. The settings used for the assays in both databases were CLDN9; primary external reference: UniProt O95484; species: Homo sapiens; Identifier: R-HSA-421271.

2.8. Expression and Survival Analyses

The clinical impact was evaluated using the Xena Functional Genomics Browser (https://xenabrowser.net/). In addition, data from 580 samples from the TCGA Stomach Cancer Study (STAD) were used to analyze the impact of Claudin-9 expression in gastric cancer patients.

For the analysis of Claudin-9 expression in the different histological types of gastric cancer (TCGA STAD study), we compared the histologic type and the gene expression by RNAseq-IlluminaHiSeq UNC for the CLDN9 gene. The statistical test to determine the differences in the expression of Claudin-9 in the histological types was one-way ANOVA.

The overall survival (OS) and progression-free interval (PFI) of the patients and their association with the expression of the CLDN9 gene generated by RNAseq-IlluminaHiSeq UNC were analyzed. For OS, the samples were divided into low- (< 3,679) (n = 222) and high- (≥ 3,679) (n = 221) CLDN9 expression. For the case of PFI, the samples were divided into low- (< 3,679) (n = 223) and high- (≥ 3,679) (n = 222) CLDN9 expression. All survival analyses were performed and analyzed using the Kaplan Meier plots.

3. Results

3.1. Prediction of Transcriptional Regulatory Elements and Promoter of CLDN9

The features of the CLDN9 gene promoter 2500 bp upstream of the transcription start point were screened. As shown in Figure 1(a), the promoter sequence has an unconventional structure as different transcriptional regulation elements are distributed throughout the 2500 bp. The Neural Network Promoter Prediction software analysis identified two sequences that interact with the GATA factors and GC and CAAT boxes. According to the conventional definition, one GATA binding sequence, two GC boxes, and the initiating region integrated a minimal promoter region. The transcription start point was located between −965 and −915 bp. A distal promoter was also detected between −2450 and −1635 bp. Three CAAT boxes integrated this promoter and one GATA binding sequence, with the transcription start point located between −2071 and −2021 bp (Figure 1(b)).

3.2. Transcription Factors

Twenty-two transcription factors were predicted by TRANSFACT to exist within the transcription start point and 2500 bp upstream (Table 1). The score of all of them is 100%, thus implying a high possibility of binding with the promoter sequence. Interestingly, most of them are strongly related to cancer initiation and progression.

The analysis performed in the Signaling Pathway Project showed GATA6 and GATA4 as the regulators of CLDN9 expression in the YCC3 and AGS epithelial cell lines, respectively, whereas KLF5 was the regulator in KATO III cells (Figures 2(a) and 2(b)).

3.3. Molecular Docking Analysis

Anchorage analysis was performed to predict the binding affinity of c-Ets-1, NF-κB, HNF-3β, Oct1, and AP-1 to the CLDN9 promoter. The docking scores obtained were −377 for Oct1, −312 for NF-κB, −276 for AP-1, −261 for c-Ets-1, and −266 for HNF-3β (Figure 3). All distances between the interacting residues were <4 Å.

3.4. Epigenetic Regulation Analysis

A comparison with the normal controls showed an increasing trend of methylation in the stomach cancer samples (Disease meth v. 2.0 STAD database). Therefore, a more exhaustive bioinformatics analysis of the promoter region was performed using the data from the cancer genome atlas.

Because of the closeness in the genomic context and their functional similarities, a comparison of the promoter's methylation between the CLDN9 and CLDN6 genes was performed. Cadherin 1 gene, a gene regulated by methylation in the gastric tissue, was added as a control. The CLDN9 gene was highly methylated in contrast to CLDN6, which showed lower levels (Figures 4(a) and 4(b)). The methylation of CDH1 was significantly lower (Figure 4(c)). The heat map results of claudin gene methylation showed transcriptional repression of the CLDN9 gene expression in gastric cancer patients (Figure 4(d)).

High- and low-risk values for the CLDN9 gene were calculated according to the median value of gene methylation. There were no significant differences in overall survival between high- and low-methylation groups (P=0.6871) (Figure 4(e)). Similarly, the group with the highest methylation remained disease-free slightly longer without disease recurrence than the group with the lowest methylation (P=0.7238) (Figure 4(f)). The progression-free interval was slightly better but not significant in the lower methylation group (P=0.1249) (Figure 4(g)).

3.5. Secondary Structure of Claudin-9

The CLDN9 gene codifies an RNA that translates a protein with 217 amino acids of 22.8 kDa. The predicted secondary structure of Claudin-9 using the SOPMA method identified α-helixes (50.69% of the sequence), extended strands (13.36% of the sequence), β-turns (5.07% of the sequence), and random coils (30.88% of the sequence) (Figure 5(a)). Interpro databases were used to identify nonconserved (blue) and nonintegrated (brown and pistachio green) elements within the protein. The most representative figure is the secondary structure prediction in which the transmembrane α-helix (blue, spiral structure), sheet (red, folding), turn (green), and coil (purple) generate an irregular curly structure (Figure 5(a)).

The sequence alignment results showed that Claudin-9 is highly similar to Claudin-6 and -8 as they possess 217 to 220 residues compared to Claudin-18 that has 261 residues. The analysis showed that there are regions present in Claudin-18 (148–159, 234–258) that are not in Claudin-6, -8, and -9.

The radial graph (Figure 5(b)) shows that more progress has been made in the detection of the expression of Claudin-9 in the tissues and cell types (0.75) than in the studies of the alteration in its expression (0.45), mentions in Pubmed (0.59), and the analysis of its transcription factors (0.45). The values below 0.7 are considered to have a low abundance of knowledge in the area.

3.6. Protein-Protein Interactions

The STRING interactome analysis showed that the first field of proteins with direct interaction or association with Claudin-9 is the claudin family proteins, such as Claudin-1, -2, -3, -8, -10, -12, -15, -16, -18, and -23, among others. In the second field, the proteins with indirect interaction with Claudin-9 are proteins, such as Cadherin-1 (CDH1), Cadherin-5 (CDH5), Occludin (OCLN), ZO1 (TJP1), ZO5 (TJP5), EPCAM, CD81, or JAM-A (F11R), among others. These proteins participate in the positive regulation of the blood-brain barrier permeability, calcium-independent cell-cell adhesion via plasma membrane, the establishment of the intestinal endothelial barrier, TJ assembly, and protein relocalization to the TJ (Figure 6(a)) (Table 2).

An analysis of the physical interaction network of Claudin-9 using the BioGRID database [72] showed 17 proteins that physically interact with Claudin-9 (Figure 6(b)). These proteins are not the typical interactors for Claudin-9, which points to its participation in still unknown processes. For instance, GRM2 and LPAR3 proteins are G protein-coupled receptors that regulate glutamate and lysophosphatidic acid uptake, respectively, or RPRM (Reprimo protein) that modulates the arrest of the p53-dependent cell cycle in the G2 phase.

Finally, an analysis of interactomes given by “textmining” between Claudin-9 and the transcription factors determined using TFSearch made it possible to determine a group of functions generally associated with four major cellular processes. (1) Cell junctions composed of other claudins. (2) Cell survival characterized by apoptotic or antiapoptotic processes, cell migration, and invasion processes; the most representative proteins involved in such processes were MAPK8, MAPK9, MAPK10, MAPK8IP1, and MMP9. (3) Cell differentiation and development, where the relevant proteins of these processes, such as the transcription factor Sox5 that participates in invasion and metastasis in gastric cancer and Sox9 that plays a role in gastric cancer development, were determined. Other important proteins in this group were the transcription factors FOXA1 and FOXA2 that have been reported as the initiating factors of a cellular transdifferentiation program that generates gastric-like tissue in lung adenocarcinomas. (4) Cellular transcription process, which included a great variety of transcription factors, such as USF1 that participates in familial combined hyperlipidemia, TCF3, which plays a significant role in B and T lymphopoiesis, or LMO2 that has a central role in erythropoiesis and hematopoietic development (Figure 6(c)).

3.7. Correlation with Survival in Gastric Cancer Patients

The overall survival of patients, based on the survival data from “The cancer genome Atlas (TCGA)” from the STAD study (TCGA Stomach Cancer), shows a significant positive effect (P=0.004) in those patients with a lower expression of Claudin-9. Their median survival was 4.7 years compared to 1.6 years in the group with the highest expression (Figure 7(a)).

The progression-free interval showed that patients with higher Claudin-9 expression have a worse prognosis, presenting disease progression at a median of 2.7 years compared to the 4.5 years observed for the low-expression group (Figure 7(b)).

4. Discussion

Claudins conform to a family of proteins with 27 human isoforms that play a crucial role in the regulation of cellular processes, such as growth, proliferation, migration, and invasion [14]. Most members of the claudin family share the same intracellular framework, however, the difference between them lies in their extracellular domains that regulate gate, barrier, and coreceptor diversity [7, 9, 12, 73]. The CLDN9 gene has four introns and is located close to the CLDN6 gene in chromosome 16 [73]. It is considered, similar to CLDN6, a developmental claudin isoform [74]. Claudin-9 is expressed in the inner ear [25], where it acts as a cation barrier [75], a process essential for hearing, and it is also a coreceptor for hepatitis C virus and C. perfringes enterotoxin [76, 77]. Its RNA is poorly expressed in the stomach (0.3 average protein transcripts per million) although the protein level is not necessarily correlated with the mRNA level (The Human Protein Atlas) [78]. Claudin-9 is related to poor prognosis in gastric cancer [23, 30, 31]. Nevertheless, the prominence of Claudin-9 in relation to its interactions, activation, and role in gastric cancer is poorly described. Claudin-9 expression is related to the increased metastatic ability of the hepatocytes by disturbing the TyK2/Stat3 signaling pathway [79], and it has been related to lymphatic metastasis in cervical carcinoma [28].

The results showed that the CLDN9 promoter possesses a minimal promoter region integrated by one GATA binding sequence, two GC boxes, the initiating region, and a distal promoter integrated by three CAAT boxes and two GATA binding sequences. The GC box sequences are considered the common transcriptional regulatory elements. The CAAT boxes signal the binding site for general transcription factors, and the sequences for the GATA factors serve as controllers for activating or repressing transcription [80]. It is possible that the function of the translated protein, cell proliferation and/or cell apoptosis, might be dependent on which promoter region binds a given transcription factor or its binding kinetics [81]. It is also possible that the binding of both promoter regions by the same transcription factor by a mediator and a modification complex is required to form a loop that initiates protein transcription [82]. It has been established that a change in the transcription factor activity dependent on the transcription factor concentration alters the expression of its targets [83].

Interestingly, 20 different transcription factors that can bind the CLDN9 promoter region with a 100% score were determined. The majority are considered the key regulators of epithelial differentiation and organ development, i.e., CP2 [84], the maintenance of the germline stem cells, i.e., USF [85], enhancers that activate transcriptional programs and cellular reprogramming, i.e., GATA1 and GATA 3 [86], favor cell growth and proliferation, i.e., AP1 and AP4 [87], and facilitate TJ formation in carcinoma cells, i.e., HNF4 [88].

ChiP-Atlas MACS2 analysis found that GATA6 and GATA4 regulate CLDN9 expression in the YCC3 and AGS gastric epithelial cancer cell lines, respectively, whereas KLF5, a transcription factor that binds to the GC boxes [89] and interacts with GATA4 and GATA6 [90] was the regulator in KATO III gastric cancer cells. It is possible that the difference may arise from the different histopathological phenotypes because KATO III is a human gastric signet ring cell adenoma cancer that can be induced to adipogenic, chondrogenic, osteogenic, and neurogenic differentiation [91].

A different analysis showed that the CLDN9 gene was highly methylated and the heat map results showed the transcriptional repression of the CLDN9 gene expression in gastric cancer patients. DNA methylation is an epigenetic mechanism recognized as a biological process that can change the activity of a DNA segment, silencing gene expression [92]. Some genes can be expressed even when they are extensively methylated [93, 94]. In relation to gastric cancer, the hypermethylation of the Claudin-11 promoter has been associated with increased invasive potential [95], and the hypermethylation of the Claudin-3 promoter is considered a predictor of poor prognosis in advanced gastric adenocarcinoma [96]. In fact, promoter hypermethylation and claudin expression have been associated with gastric cancer TNM stage [97, 98].

As expected, Claudin-9 expression is associated with shorter and progression-free survival. The expression of dedifferentiation markers, such as CD44, CD133, Claudin-6 or -9, in the majority of epithelial cancers [99–103] is associated with poor survival.

5. Conclusion

Claudin-9 is a TJ protein involved in key biological processes. Its expression may be regulated by many mechanisms, however, its overexpression or the methylation status of the promoter may be a prognostic factor in gastric cancer.

Acknowledgments

Elizabeth Hernández-Nava was a recipient of a postdoctoral fellowship by the Consejo Nacional de Ciencia y Tecnología of México (CONACYT). This work was supported by the Programa de Apoyo a Proyectos de Investigación e Innovación Tecnológica (PAPIIT) of the Universidad Nacional Autónoma de México (UNAM) grants IN218019 and IN221519.

Data Availability

The data used to support the findings of this study are available from the corresponding author upon request.

Conflicts of Interest

The authors declare that none of them has conflicts of interest.

Figure 1 CLDN9 gene promoter region. (a) Elements of transcription regulation of the region 2.5 kB upstream (5′) to TSS to 0.5 kB downstream (3′). (b) Distal (score 1.00) and Minimun (score 0.89) promoter regions determined by Neural Network Promoter Prediction software.

Figure 2 Transcription factors bound to the CLDN9 promoter region. (a) Binding score of transcription factors bound to the CLDN9 promoter region determined by ChiP assays (ChiP-Atlas MACS2) obtained from the Signaling Pathway Project. (b) Cell lines used to determine the transcription factors involved in the regulation of cldn9 gene.

Figure 3 Molecular docking of the CLDN9 promoter region with transcription factors. Docking between the CLDN9 promoter (red/blue) and (a) Oct1 (green), (b) NF-kB (yellow), (c) AP1 (pink), (d) C-ets-1 (orange), and (e) HNF-3β (purple). Right side panels represent a zoom image of the interaction areas and the interacting nucleotides. DS = docking score.

Figure 4 Methylation of CLDN9, CLDN6, and CDH1 genes. Methylation level of (a) CLDN9, (b) CLDN6, and (c) CDH1 under gastric cancer condition compared with normal tissue. (d) Heatmap of the methylation of CLDN9, CLDN6, and CDH1 genes. (e) Overall Survival probability between CLDN9 high-methylation level (≥0.5050 average) vs. low-methylation level (<0.5050 average), P=0.6871, Log-Rank = 0.162. (f) Disease-free interval between CLDN9 high-methylation level (≥0.5050 average) vs. low-methylation level (<0.5050 average), P=0.7238, Log-Rank = 0.125. (g) Progression-free interval between CLDN9 high-methylation level (≥0.5050 average) vs. low-methylation level (<0.5050 average), P=0.3450, Log-Rank = 0.892.

Figure 5 Sequence and structural analysis of Claudin-9. (a) Sequence comparison between Claudin-9 and those of other closely related claudins. The structural components of Claudin-9 are enlisted, and (b) the analysis of the knowledge of Claudin-9 based on its molecular components and characteristics, as well as its interactions.

Figure 6 Protein-protein interaction network of Claudin-9. (a) The analysis of interaction by confidence using Reactome and (b) protein-protein interaction network by STRING. The lines denote physical or theoretical interactions, field 1 to 10, field 2 to 10 (the thicker the line and the closer they are to each other, the greater the interaction confidence), and (c) PPI interactions of Claudin-9 focused on related transcription factors. The background colored fields indicate functional affinity. The green field shows the functional affinity of the different claudins of the interaction network in the biological processes “Tight junction assembly/Disassmably (GOTERMS: GO: 0120192/GO: 1905071).” The red field shows the functional affinity of the transcription factors and other proteins participating in cell differentiation and the cell development process. The yellow field mainly shows the GATA transcription factors and other genes related to the development and progression of cancer, including gastric cancer.

Figure 7 Expression of Claudin-9 and its clinical impact. (a) Claudin-9 expression and Overall Survival based on a high (≥3.679) vs. low (<3.679) expression, (b) Progression-free interval based on high (≥3.679) vs. low (<3.679) Claudin-9 expression.

Table 1 Transcription factors.

Transcription factors	Score	Strand position	Sequence	
ZID	100	61 (+)	gGGCTCcagcaca	
CP2	100	69 (+)	gcacacCCCAG	
c-Ets-1	100	284 (−)	tgccTCCGGT	
Nkx2-5	100	464 (+)	tcAAGTG	
Elk-1	100	602 (−)	aaccTTCCGattta	
USF	100	714 (−)	acctCGTGAa	
MyoD	100	771 (−)	ccgcACCTgcc	
AREB6	100	771 (+)	ccgcACCTgcc	
SOX-9	100	799 (+)	agacaACAATcctc	
Sox-5	100	801 (+)	acaACAATcc	
HNF-4	100	924 (−)	agtgggtCTTTGaccaaag	
c-Rel	100	1055 (+)	gggttTTTCC	
GATA-3	100	1318 (+)	ggaGATCTta	
v-Myb	100	1412 (−)	ggCCGTTgcc	
RFX1	100	1414 (−)	ccGTTGCcagggcgatgc	
NF-kB	100	1479 (+)	cgGGGACcttcccc	
HNF-3β	100	1586 (+)	gggcaTGTTTgcatc	
Oct-1	100	1589 (−)	catgTTTGCatcacg	
AP-4	100	1624 (+)	agaggCAGCTggggaggg	
GATA-1	100	1919 (−)	tccccTATCCcggc	
E47	100	2082 (+)	cagtgcgTCTGGaggg	
AP-1	100	2391 (+)	ctgAGTCAc	

Table 2 STRING interactome.

Protein	Function	Type of interaction	Curated	References	
EPCAM	The epithelial cell adhesion molecule's precursor participates in migration, proliferation, and cellular differentiation. In cancer, it promotes tumor progression by the EGFR pathway.	Textmining	STRING	[33, 34]	
	
CD81	The tetraspanin family is a cell-surface protein and plays an essential role in developing cellular growth and activating the B and T cells. It is expressed in most types of cancers.	Textmining	STRING	[35, 36]	
	
PVRL3	Poliovirus receptor-related 3, also called Nectin-3, forms part of the adherens junctions. PVLR3 has been implicated in tumor progression in lung, pancreatic, and ovarian adenocarcinomas.	Textmining	STRING	[37–39]	
	
VWF	Von Willebrand factor, its primary role is in thrombus formation and blood coagulation. VWF has been reported to participate in inflammation, angiogenesis, and metastasis in various cancers, including gastric cancer.	Textmining	STRING	[40, 41]	
	
F11R	Junctional adhesion molecule A (JAM-A) plays a role in the epithelial tight junction formation. JAM-A has been reported to promote proliferation and inhibit apoptosis in gastric cancer.	Textmining	STRING	[42, 43]	
	
CDH5	Cadherin-5, this protein plays a role in endothelial adherens junction assembly and maintenance. In cancer, it has been reported to be involved in progression and metastasis. In gastric cancer, its expression correlates with poor survival.	Textmining	STRING	[44–46]	
	
TJP1, TJP2, TJP3	Tight junction proteins ZO-1, ZO-2, and ZO-3 are closely related scaffolding proteins that link the tight junction (TJ) transmembrane proteins, such as claudins, junctional adhesion molecules, and occludin to the actin cytoskeleton. Their expression is altered during tumor development, metastasis, and poor prognosis in several types of cancers.	Texmining	STRING	[47–52]	
	
OCLN	Occludin may play a role in forming and regulating the tight junction (TJ) paracellular permeability barrier. In gastric cancer, the downregulation of some occludins is associated with tumor aggressiveness and survival.	Texmining	STRING	[53, 54]	
	
RUNX1	Runt-related transcription factor 1 is a transcription factor that modulates the target genes involved in the development of immune cells. In colorectal cancer, it promotes tumor metastasis by activating the Wnt/β-catenin signaling pathway and EMT.	Textmining	STRING	[55–57]	
	
CBFB	Core-binding factor subunit beta, a non-DNA-binding regulatory subunit that allosterically enhances the sequence-specific DNA-binding capacity of RUNX—involved in hematopoiesis and osteogenesis. In breast cancer, it has been observed as a tumor suppressor.	Textmining	STRING	[58, 59]	
	
HNF1A	Hepatocyte nuclear factor 1-alpha is a transcriptional activator that regulates the tissue-specific expression of multiple genes, especially in the pancreatic islet cells and the liver. Recently, it has been reported to facilitate gastric cancer tumor progression.	Textmining	STRING	[60, 61]	
	
FXYD2	Sodium/potassium-transporting ATPase subunit gamma may form the receptor site for cardiac glycoside binding or modulating the sodium ATPase's transport function. It may be involved in tumor growth.	Textmining	STRING	[62, 63]	
	
CAPN9	Calpain-9 is involved in apoptosis, cellular proliferation, and cell motility. Calpain expression is altered during tumorigenesis and the proteolysis of numerous substrates, such as inhibitors of nuclear factor-κB and proto-oncogenes.	Texmining	STRING	[64–66]	
	
MFHAS1	Malignant fibrous histiocytoma-amplified sequence 1 functions in innate immunity, more specifically, in the inflammatory response as a regulator of the Toll-like receptor TLR2 and TLR4 signaling pathways. MFHAS1 promotes colorectal cancer progress by regulating the polarization of tumor-associated macrophages via the STAT6 signaling pathway	Textmining	STRING	[67, 68]	
	
PPP1R3B	Protein phosphatase 1 regulatory subunit 3B acts as a glycogen-targeting subunit for phosphatase PP1 and promotes glycogen synthesis. In cancer, it has been used to treat a melanoma patient with an immunological focus.	Textmining	STRING	[69, 70]	
	
ESAM	Endothelial cell-selective adhesion molecule's in vitro functional profile strongly suggests a role in cell-cell interactions critical for vascular development or function.	Textmining	STRING	[71]
==== Refs
1 Ferlay J. Colombet M. Soerjomataram I. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods International Journal of Cancer 2019 144 8 1941 1953 10.1002/ijc.31937 2-s2.0-85057728011 30350310
2 De Re V. Molecular features distinguish gastric cancer subtypes International Journal of Molecular Sciences 2018 19 10.3390/ijms19103121 2-s2.0-85054895187
3 Ling Y. Watanabe Y. Nagahashi M. Genetic profiling for diffuse type and genomically stable subtypes in gastric cancer Computational and Structural Biotechnology Journal 2020 18 3301 3308 10.1016/j.csbj.2020.10.021 33240471
4 Puneet K. H. R. Kazmi H. R. Kumari S. Tiwari S. Khanna A. Narayan G. Epigenetic mechanisms and events in gastric cancer-emerging novel biomarkers Pathology and Oncology Research 2018 24 4 757 770 10.1007/s12253-018-0410-z 2-s2.0-85044041031 29552712
5 Colaprico A. Olsen C. Bailey M. H. Interpreting pathways to discover cancer driver genes with moonlight Nature Communications 2020 11 1 p. 69 10.1038/s41467-019-13803-0
6 Berger M. F. Mardis E. R. The emerging clinical relevance of genomics in cancer medicine Nature Reviews Clinical Oncology 2018 15 6 353 365 10.1038/s41571-018-0002-6 2-s2.0-85044616685
7 Anderson J. M. Van Itallie C. M. Physiology and function of the tight junction Cold Spring Harbor Perspectives in Biology 2009 1 2 a002584 10.1101/cshperspect.a002584
8 Heinemann U. Schuetz A. Structural features of tight-junction proteins International Journal of Molecular Sciences 2019 20 10.3390/ijms20236020
9 Günzel D. Yu A. S. Claudins and the modulation of tight junction permeability Physiological Reviews 2013 93 525 569 10.1152/physrev.00019.2012 2-s2.0-84878506887 23589827
10 Li J. Dysregulated expression of claudins in cancer (review) Oncology Letters 2021 22 3 p. 641 10.3892/ol.2021.12902 34386063
11 Taylor A. Warner M. Mendoza C. Chimeric claudins: a new tool to study tight junction structure and function International Journal of Molecular Sciences 2021 22 10.3390/ijms22094947
12 Otani T. Nguyen T. P. Tokuda S. Claudins and JAM-A coordinately regulate tight junction formation and epithelial polarity Journal of Cell Biology 2019 218 10 3372 3396 10.1083/jcb.201812157 2-s2.0-85072992254 31467165
13 Bhat A. A. Uppada S. Achkar I. W. Tight junction proteins and signaling pathways in cancer and inflammation: a functional crosstalk Frontiers in Physiology 2018 9 p. 1942 10.3389/fphys.2018.01942 2-s2.0-85065525950
14 Gowrikumar S. Singh A. B. Dhawan P. Role of claudin proteins in regulating cancer stem cells and chemoresistance-potential implication in disease prognosis and therapy International Journal of Molecular Sciences 2019 21 10.3390/ijms21010053
15 Kwon M. Emerging roles of claudins in human cancer International Journal of Molecular Sciences 2013 14 9 18148 18180 10.3390/ijms140918148 2-s2.0-84884240720 24009024
16 Salvador E. Burek M. Förster C. Y. Tight junctions and the tumor microenvironment Current Pathobiology Reports 2016 4 3 135 145 10.1007/s40139-016-0106-6 2-s2.0-85003026481 27547510
17 Osanai M. Takasawa A. Murata M. Sawada N. Claudins in cancer: bench to bedside Pflügers Archiv—European Journal of Physiology 2017 469 1 55 67 10.1007/s00424-016-1877-7 2-s2.0-84987651063 27624415
18 Eftang L. L. Esbensen Y. Tannæs T. M. Blom G. P. Bukholm I. R. Bukholm G. Up-regulation of CLDN1 in gastric cancer is correlated with reduced survival BMC Cancer 2013 13 1 p. 586 10.1186/1471-2407-13-586 2-s2.0-84889854122
19 Jung H. Jun K. H. Jung J. H. Chin H. M. Park W. B. The expression of claudin-1, claudin-2, claudin-3, and claudin-4 in gastric cancer tissue Journal of Surgical Research 2011 167 2 e185 e191 10.1016/j.jss.2010.02.010 2-s2.0-79952382617 20462599
20 Zayed H. The identification of highly upregulated genes in claudin-low breast cancer through an integrative bioinformatics approach Computers in Biology and Medicine 2020 127 103806 10.1016/j.compbiomed.2020.103806
21 Gao M. Li W. Wang H. Wang G. The distinct expression patterns of claudin-10, -14, -17 and E-cadherin between adjacent non-neoplastic tissues and gastric cancer tissues Diagnostic Pathology 2013 8 1 p. 205 10.1186/1746-1596-8-205 2-s2.0-84894613095 24325792
22 Hwang T.-L. Changchien T.-T. Wang C.-C. Wu C.-M. Claudin-4 expression in gastric cancer cells enhances the invasion and is associated with the increased level of matrix metalloproteinase-2 and -9 expression Oncology Letters 2014 8 3 1367 1371 10.3892/ol.2014.2295 2-s2.0-84904248460 25120725
23 Kohmoto T. Masuda K. Shoda K. Claudin-6 is a single prognostic marker and functions as a tumor-promoting gene in a subgroup of intestinal type gastric cancer Gastric Cancer 2020 23 3 403 417 10.1007/s10120-019-01014-x 31654186
24 Jun K.-H. Kim J.-H. Jung J.-H. Choi H.-J. Chin H.-M. Expression of claudin-7 and loss of claudin-18 correlate with poor prognosis in gastric cancer International Journal of Surgery 2014 12 2 156 162 10.1016/j.ijsu.2013.11.022 2-s2.0-84893973181 24333468
25 Kitajiri S.-i. Furuse M. Morita K. Expression patterns of claudins, tight junction adhesion molecules, in the inner ear Hearing Research 2004 187 1-2 25 34 10.1016/s0378-5955(03)00338-1 2-s2.0-0347123651 14698084
26 Sharma R. K. Chheda Z. S. Das Purkayastha B. P. Gomez-Gutierrez J. G. Jala V. R. Haribabu B. A spontaneous metastasis model reveals the significance of claudin-9 overexpression in lung cancer metastasis Clinical & Experimental Metastasis 2016 33 3 263 275 10.1007/s10585-015-9776-4 2-s2.0-84949947428 26669782
27 Hong L. Wu Y. Feng J. Overexpression of the cell adhesion molecule claudin-9 is associated with invasion in pituitary oncocytomas Human Pathology 2014 45 12 2423 2429 10.1016/j.humpath.2014.08.006 2-s2.0-84912570078 25281028
28 Zhu J. Wang R. Cao H. Expression of claudin-5, -7, -8 and -9 in cervical carcinoma tissues and adjacent non-neoplastic tissues International Journal of Clinical and Experimental Pathology 2015 8 9479 9486 26464708
29 Kang H. Wang N. Wang X. A glycolysis-related gene signature predicts prognosis of patients with esophageal adenocarcinoma Aging 2020 12 24 25828 25844 10.18632/aging.104206 33234735
30 Rendón-Huerta E. Teresa F. Teresa G. M. Distribution and expression pattern of claudins 6, 7, and 9 in diffuse- and intestinal-type gastric adenocarcinomas Journal of Gastrointestinal Cancer 2010 41 52 59 19960275
31 Zavala-Zendejas V. E. Torres-Martinez A. C. Salas-Morales B. Fortoul T. I. Montaño L. F. Rendon-Huerta E. P. Claudin-6, 7, or 9 overexpression in the human gastric adenocarcinoma cell line AGS increases its invasiveness, migration, and proliferation rate Cancer Investigation 2011 29 1 1 11 10.3109/07357907.2010.512594 2-s2.0-78650486487 20874001
32 Combet C. Blanchet C. Geourjon C. Deléage G. NPS@: network protein sequence analysis Trends in Biochemical Sciences 2000 25 3 147 150 10.1016/s0968-0004(99)01540-6 2-s2.0-0034161321 10694887
33 Huang L. Yang Y. Yang F. Functions of EpCAM in physiological processes and diseases (review) International Journal of Molecular Medicine 2018 42 1771 1785 10.3892/ijmm.2018.3764 2-s2.0-85052400088 30015855
34 Chen H.-N. Liang K.-H. Lai J.-K. EpCAM signaling promotes tumor progression and protein stability of PD-L1 through the EGFR pathway Cancer Research 2020 80 22 5035 5050 10.1158/0008-5472.can-20-1264 32978170
35 Levy S. Function of the tetraspanin molecule CD81 in B and T cells Immunologic Research 2014 58 2-3 179 185 10.1007/s12026-014-8490-7 2-s2.0-84901586550 24522698
36 Vences-Catalán F. Duault C. Kuo C.-C. Rajapaksa R. Levy R. Levy S. CD81 as a tumor target Biochemical Society Transactions 2017 45 2 531 535 10.1042/bst20160478 2-s2.0-85018471161 28408492
37 Fujito T. Ikeda W. Kakunaga S. Inhibition of cell movement and proliferation by cell-cell contact-induced interaction of Necl-5 with nectin-3 Journal of Cell Biology 2005 171 1 165 173 10.1083/jcb.200501090 2-s2.0-26444569379 16216929
38 Izumi H. Hirabayashi K. Nakamura N. Nakagohri T. Nectin expression in pancreatic adenocarcinoma: nectin-3 is associated with a poor prognosis Surgery Today 2015 45 4 487 494 10.1007/s00595-015-1126-2 2-s2.0-84925487320 25690753
39 Xu F. Si X. Wang J. Yang A. Qin T. Yang Y. Nectin-3 is a new biomarker that mediates the upregulation of MMP2 and MMP9 in ovarian cancer cells Biomedicine & Pharmacotherapy 2019 110 139 144 10.1016/j.biopha.2018.11.020 2-s2.0-85056754693 30469078
40 Hassan M. I. Saxena A. Ahmad F. Structure and function of von Willebrand factor Blood Coagulation and Fibrinolysis 2012 23 1 11 22 10.1097/mbc.0b013e32834cb35d 2-s2.0-84855190263 22089939
41 Patmore S. Dhami S. P. S. O’Sullivan J. M. Von Willebrand factor and cancer; metastasis and coagulopathies Journal of Thrombosis and Haemostasis 2020 18 10 2444 2456 10.1111/jth.14976 32573945
42 Sobocka M. B. Sobocki T. Banerjee P. Cloning of the human platelet F11 receptor: a cell adhesion molecule member of the immunoglobulin superfamily involved in platelet aggregation Blood 2000 95 8 2600 2609 10.1182/blood.v95.8.2600.008k28_2600_2609 10753840
43 Ikeo K. Oshima T. Shan J. Junctional adhesion molecule-A promotes proliferation and inhibits apoptosis of gastric cancer Hepato-Gastroenterology 2015 62 540 545 25916097
44 Brasch J. Harrison O. J. Ahlsen G. Structure and binding mechanism of vascular endothelial cadherin: a divergent classical cadherin Journal of Molecular Biology 2011 408 1 57 73 10.1016/j.jmb.2011.01.031 2-s2.0-79953254024 21269602
45 Casal J. I. Bartolomé R. A. Beyond N-cadherin, relevance of cadherins 5, 6 and 17 in cancer progression and metastasis International Journal of Molecular Sciences 2019 20 10.3390/ijms20133373 2-s2.0-85071327057
46 Higuchi K. Inokuchi M. Takagi Y. Cadherin 5 expression correlates with poor survival in human gastric cancer Journal of Clinical Pathology 2017 70 3 217 221 10.1136/jclinpath-2016-203640 2-s2.0-85014647101 27466381
47 Kremerskothen J. Stölting M. Wiesner C. Zona occludens proteins modulate podosome formation and function The FASEB Journal 2011 25 2 505 514 10.1096/fj.10-155598 2-s2.0-79551654017 20930113
48 Chlenski A. Ketels K. V. Korovaitseva G. I. Talamonti M. S. Oyasu R. Scarpelli D. G. Organization and expression of the human zo-2 gene (tjp-2) in normal and neoplastic tissues Biochimica et Biophysica Acta (BBA)—Gene Structure and Expression 2000 1493 3 319 324 10.1016/s0167-4781(00)00185-8 2-s2.0-0034597347 11018256
49 Capaldo C. T. Koch S. Kwon M. Laur O. Parkos C. A. Nusrat A. Tight function zonula occludens-3 regulates cyclin D1-dependent cell proliferation Molecular Biology of the Cell 2011 22 10 1677 1685 10.1091/mbc.e10-08-0677 2-s2.0-79955973354 21411630
50 Lee S. H. Paek A. R. Yoon K. Kim S. H. Lee S. Y. You H. J. Tight junction protein 1 is regulated by transforming growth factor-β and contributes to cell motility in NSCLC cells BMB Reports 2015 48 2 115 120 10.5483/bmbrep.2015.48.2.035 2-s2.0-84925442525 25027596
51 Tan X. Zhou L. Wang W. Genomic analysis of invasion-metastasis-related factors in pancreatic cancer cells Experimental and Therapeutic Medicine 2010 1 211 216 10.3892/etm_00000034 2-s2.0-77955348486 23136617
52 Martin T. A. Watkins G. Mansel R. E. Jiang W. G. Corrigendum to “loss of tight junction plaque molecules in breast cancer tissues is associated with a poor prognosis in patients with breast cancer” [Eur j cancer 40 (18) (2004) 2717–2725] European Journal of Cancer 2018 88 115 116 10.1016/j.ejca.2017.11.001 2-s2.0-85035012302 29174182
53 Suzuki T. Elias B. C. Seth A. PKC regulates occludin phosphorylation and epithelial tight junction integrity Proceedings of the National Academy of Sciences 2009 106 1 61 66 10.1073/pnas.0802741106 2-s2.0-58549096092
54 Ohtani S. Terashima M. Satoh J. Expression of tight-junction-associated proteins in human gastric cancer: downregulation of claudin-4 correlates with tumor aggressiveness and survival Gastric Cancer 2009 12 1 43 51 10.1007/s10120-008-0497-0 2-s2.0-65449143935 19390931
55 Fujimoto T. Anderson K. Jacobsen S. E. W. Nishikawa S.-i. Nerlov C. Cdk6 blocks myeloid differentiation by interfering with Runx1 DNA binding and Runx1-C/EBPα interaction The EMBO Journal 2007 26 9 2361 2370 10.1038/sj.emboj.7601675 2-s2.0-34247571525 17431401
56 Ono M. Yaguchi H. Ohkura N. Foxp3 controls regulatory T-cell function by interacting with AML1/Runx1 Nature 2007 446 7136 685 689 10.1038/nature05673 2-s2.0-34247215187 17377532
57 Li Q. Lai Q. He C. RUNX1 promotes tumour metastasis by activating the Wnt/β-catenin signalling pathway and EMT in colorectal cancer Journal of Experimental & Clinical Cancer Research 2019 38 1 p. 334 10.1186/s13046-019-1330-9 2-s2.0-85070991615
58 Adya N. Castilla L. H. Liu P. P. Function of CBFβ/Bro proteins Seminars in Cell & Developmental Biology 2000 11 5 361 368 10.1006/scdb.2000.0189 2-s2.0-0034351884 11105900
59 Malik N. Yan H. Moshkovich N. The transcription factor CBFB suppresses breast cancer through orchestrating translation and transcription Nature Communications 2019 10 1 p. 2071 10.1038/s41467-019-10102-6 2-s2.0-85065303743
60 Rose R. B. Bayle J. H. Endrizzi J. A. Cronk J. D. Crabtree G. R. Alber T. Structural basis of dimerization, coactivator recognition and MODY3 mutations in HNF-1alpha Nature Structural Biology 2000 7 744 748 10.1038/78966 2-s2.0-0033813065 10966642
61 Ma P. Li L. Liu F. Zhao Q. HNF1A-Induced lncRNA HCG18 facilitates gastric cancer progression by upregulating DNAJB12 via miR-152-3p OncoTargets and Therapy 2020 13 7641 7652 10.2147/ott.s253391 32801777
62 Geering K. Function of FXYD proteins, regulators of Na, K-ATPase Journal of Bioenergetics and Biomembranes 2005 37 6 387 392 10.1007/s10863-005-9476-x 2-s2.0-33646569462 16691470
63 Hsu I.-L. Chou C.-Y. Wu Y.-Y. Targeting FXYD2 by cardiac glycosides potently blocks tumor growth in ovarian clear cell carcinoma Oncotarget 2016 7 39 62925 62938 10.18632/oncotarget.7497 2-s2.0-84993990175 26910837
64 Momeni H. R. Role of calpain in apoptosis Cell Journal 2011 13 65 72 23507938
65 Zhang Y. Liu N. M. Wang Y. Youn J. Y. Cai H. Endothelial cell calpain as a critical modulator of angiogenesis Biochimica et Biophysica Acta—Molecular Basis of Disease 2017 1863 6 1326 1335 10.1016/j.bbadis.2017.03.021 2-s2.0-85018937987 28366876
66 Storr S. J. Carragher N. O. Frame M. C. Parr T. Martin S. G. The calpain system and cancer Nature Reviews Cancer 2011 11 5 364 374 10.1038/nrc3050 2-s2.0-79955458657 21508973
67 Zhong J. Shi Q.-Q. Zhu M.-M. MFHAS1 is associated with sepsis and stimulates TLR2/NF-κB signaling pathway following negative regulation PLoS One 2015 10 11 e0143662 10.1371/journal.pone.0143662 2-s2.0-84957990919
68 Chen W. Xu Y. Zhong J. MFHAS1 promotes colorectal cancer progress by regulating polarization of tumor-associated macrophages via STAT6 signaling pathway Oncotarget 2016 7 48 78726 78735 10.18632/oncotarget.12807 2-s2.0-84998854318 27783989
69 Mehta M. B. Shewale S. V. Sequeira R. N. Millar J. S. Hand N. J. Rader D. J. Hepatic protein phosphatase 1 regulatory subunit 3B (Ppp1r3b) promotes hepatic glycogen synthesis and thereby regulates fasting energy homeostasis Journal of Biological Chemistry 2017 292 25 10444 10454 10.1074/jbc.m116.766329 2-s2.0-85021662979 28473467
70 Lu Y.-C. Yao X. Li Y. F. Mutated PPP1R3B is recognized by T cells used to treat a melanoma patient who experienced a durable complete tumor regression The Journal of Immunology 2013 190 12 6034 6042 10.4049/jimmunol.1202830 2-s2.0-84879101382 23690473
71 Hirata K.-i. Ishida T. Penta K. Cloning of an immunoglobulin family adhesion molecule selectively expressed by endothelial cells Journal of Biological Chemistry 2001 276 19 16223 16231 10.1074/jbc.m100630200 2-s2.0-0035844164 11279107
72 Luck K. Kim D.-K. Lambourne L. A reference map of the human binary protein interactome Nature 2020 580 7803 402 408 10.1038/s41586-020-2188-x 32296183
73 Krause G. Winkler L. Mueller S. L. Haseloff R. F. Piontek J. Blasig I. E. Structure and function of claudins Biochimica et Biophysica Acta (BBA)—Biomembranes 2008 1778 3 631 645 10.1016/j.bbamem.2007.10.018 2-s2.0-39849091788 18036336
74 Abuazza G. Becker A. Williams S. S. Claudins 6, 9, and 13 are developmentally expressed renal tight junction proteins American Journal of Physiology—Renal Physiology 2006 291 6 F1132 F1141 10.1152/ajprenal.00063.2006 2-s2.0-33750742090 16774906
75 Nakano Y. Kim S. H. Kim H.-M. A claudin-9-based ion permeability barrier is essential for hearing PLoS Genetics 2009 5 8 e1000610 10.1371/journal.pgen.1000610 2-s2.0-70149108589
76 Fofana I. Zona L. Thumann C. Functional analysis of claudin-6 and claudin-9 as entry factors for hepatitis C virus infection of human hepatocytes by using monoclonal antibodies Journal of Virology 2013 87 18 10405 10410 10.1128/jvi.01691-13 2-s2.0-84883261383 23864633
77 Vecchio A. J. Stroud R. M. Claudin-9 structures reveal mechanism for toxin-induced gut barrier breakdown Proceedings of the National Academy of Sciences 2019 116 36 17817 17824 10.1073/pnas.1908929116 2-s2.0-85071788945
78 Uhlén M. Fagerberg L. Hallström B. M. Proteomics. Tissue-based map of the human proteome Science 2015 347 6220 1260419 10.1126/science.1260419 2-s2.0-84920269464
79 Liu H. Wang M. Wang M. Liang N. Guan L. Claudin-9 enhances the metastatic potential of hepatocytes via Tyk2/Stat3 signaling Turkish Journal of Gastroenterology 2019 30 8 722 732 10.5152/tjg.2019.18513 2-s2.0-85071539845
80 Lentjes M. H. Niessen H. E. Akiyama Y. de Bruïne A. P. Melotte V. van Engeland M. The emerging role of GATA transcription factors in development and disease Expert Reviews in Molecular Medicine 2016 18 p. e3 10.1017/erm.2016.2 2-s2.0-84960145929
81 Culyba M. J. Ordering up gene expression by slowing down transcription factor binding kinetics Current Genetics 2019 65 2 401 406 10.1007/s00294-018-0896-7 2-s2.0-85055724436 30353359
82 D’Alessio J. A. Wright K. J. Tjian R. Shifting players and paradigms in cell-specific transcription Molecular Cell 2009 36 6 924 931 10.1016/j.molcel.2009.12.011 2-s2.0-72149130298 20064459
83 Carey L. B. van Dijk D. Sloot P. M. A. Kaandorp J. A. Segal E. Promoter sequence determines the relationship between expression level and noise PLoS Biology 2013 11 4 e1001528 10.1371/journal.pbio.1001528 2-s2.0-84876991257
84 Ming Q. Roske Y. Schuetz A. Structural basis of gene regulation by the Grainyhead/CP2 transcription factor family Nucleic Acids Research 2018 46 4 2082 2095 10.1093/nar/gkx1299 2-s2.0-85041650348 29309642
85 Faisal I. Cisneros-Montalvo S. Hamer G. Transcription factor USF1 is required for maintenance of germline stem cells in male mice Endocrinology 2019 160 5 1119 1136 10.1210/en.2018-01088 2-s2.0-85065082050 30759202
86 Tanaka H. Takizawa Y. Takaku M. Interaction of the pioneer transcription factor GATA3 with nucleosomes Nature Communications 2020 11 1 p. 4136 10.1038/s41467-020-17959-y
87 Yoshitomi Y. Ikeda T. Saito-Takatsuji H. Yonekura H. Emerging role of AP-1 transcription factor JunB in angiogenesis and vascular development International Journal of Molecular Sciences 2021 22 6 10.3390/ijms22062804
88 Chiba H. Gotoh T. Kojima T. Hepatocyte nuclear factor (HNF)-4α triggers formation of functional tight junctions and establishment of polarized epithelial morphology in F9 embryonal carcinoma cells Experimental Cell Research 2003 286 2 288 297 10.1016/s0014-4827(03)00116-2 2-s2.0-0037621983 12749857
89 Dong J.-T. Chen C. Essential role of KLF5 transcription factor in cell proliferation and differentiation and its implications for human diseases Cellular and Molecular Life Sciences 2009 66 16 2691 2706 10.1007/s00018-009-0045-z 2-s2.0-68549104124 19448973
90 Luo Y. Chen C. The roles and regulation of the KLF5 transcription factor in cancers Cancer Science 2021 112 6 2097 2117 10.1111/cas.14910 33811715
91 Shah S. Pocard M. Mirshahi M. Targeting the differentiation of gastric cancer cells (KATO-III) downregulates epithelial-mesenchymal and cancer stem cell markers Oncology Reports 2019 42 670 678 31233198
92 Suzuki M. M. Bird A. DNA methylation landscapes: provocative insights from epigenomics Nature Reviews Genetics 2008 9 6 465 476 10.1038/nrg2341 2-s2.0-43749098985
93 Zhang Y. Liu C. Cheng H. DNA methylation and its effects on gene expression during primary to secondary growth in poplar stems BMC Genomics 2020 21 1 p. 498 10.1186/s12864-020-06902-6 32689934
94 Mashhadikhan M. Kheiri H. Dehghanifard A. DNA methylation and gene expression of sFRP2, sFRP4, Dkk 1, and Wif1 during osteoblastic differentiation of bone marrow derived mesenchymal stem cells Journal of Oral Biosciences 2020 62 4 349 356 10.1016/j.job.2020.08.001 32835781
95 Agarwal R. Mori Y. Cheng Y. Silencing of claudin-11 is associated with increased invasiveness of gastric cancer cells PLoS One 2009 4 11 e8002 10.1371/journal.pone.0008002 2-s2.0-71049120285
96 Zhang Z. Yu W. Chen S. Chen Y. Chen L. Zhang S. Methylation of the claudin3 promoter predicts the prognosis of advanced gastric adenocarcinoma Oncology Reports 2018 40 49 60 29749528
97 Sano T. Coit D. G. Kim H. H. Proposal of a new stage grouping of gastric cancer for TNM classification: international gastric cancer association staging project Gastric Cancer 2017 20 2 217 225 10.1007/s10120-016-0601-9 2-s2.0-84958776611 26897166
98 Xiang R. Fu T. Gastrointestinal adenocarcinoma analysis identifies promoter methylation-based cancer subtypes and signatures Scientific Reports 2020 10 1 21234 10.1038/s41598-020-78228-y
99 Ma Y.-C. Yang J.-Y. Yan L.-N. Relevant markers of cancer stem cells indicate a poor prognosis in hepatocellular carcinoma patients: a meta-analysis European Journal of Gastroenterology and Hepatology 2013 25 9 1007 1016 10.1097/meg.0b013e32836019d8 2-s2.0-84881373126 23478672
100 Xu H. Tian Y. Yuan X. The role of CD44 in epithelial-mesenchymal transition and cancer development OncoTargets and Therapy 2015 8 3783 3792 10.2147/OTT.S95470 2-s2.0-84949982731 26719706
101 Bellmunt J. Stem-like signature predicting disease progression in early stage bladder cancer. The role of E2F3 and SOX4 Biomedicines 2018 6 10.3390/biomedicines6030085 2-s2.0-85063956246
102 Lu L. Wu M. Sun L. Clinicopathological and prognostic significance of cancer stem cell markers CD44 and CD133 in patients with gastric cancer: a comprehensive meta-analysis with 4729 patients involved Medicine 2016 95 42 e5163 10.1097/md.0000000000005163 2-s2.0-84995694855
103 Prat A. Parker J. S. Karginova O. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer Breast Cancer Research 2010 12 5 p. R68 10.1186/bcr2635 2-s2.0-78049308800
